Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
GLP-1 receptor antagonist
age
basal insulin
disease duration
iGlarLixi
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
03 Jan 2024
03 Jan 2024
Historique:
revised:
30
11
2023
received:
23
10
2023
accepted:
03
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
aheadofprint
Résumé
To evaluate the effect of age and disease duration on the efficacy and safety of iGlarLixi versus insulin glargine 100 units/ml (iGlar) or lixisenatide (Lixi) alone in Asian people with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin ± oral antidiabetic drugs (LixiLan-L-CN). In this post hoc analysis, the glycated haemoglobin (HbA1c) changes were assessed from baseline to week 24 (LixiLan-O-AP) or 30 (LixiLan-L-CN) in subgroups defined by baseline age (<65, ≥65 years) and duration of T2D. The proportion who achieved the composite of HbA1c <7% (<53.0 mmol/mol) without weight gain and without symptomatic hypoglycaemia (plasma glucose ≤3.9 mmol/L) and the incidences of hypoglycaemia and gastrointestinal disorders were also analysed. HbA1c reductions were consistently greater with iGlarLixi versus iGlar or Lixi across all subgroups, including participants aged ≥65 years and those with T2D for ≥15 or ≥20 years. Greater proportions of participants achieved HbA1c <7% (<53.0 mmol/mol) without weight gain or hypoglycaemia with iGlarLixi versus iGlar or Lixi, regardless of age or T2D duration. Hypoglycaemia incidence was similar with iGlarLixi versus iGlar across most subgroups; the incidence of gastrointestinal disorders was lower with iGlarLixi versus Lixi in all subgroups. iGlarLixi showed consistent efficacy and safety across all age and disease duration subgroups in Asian people with uncontrolled T2D, including older individuals and those with longstanding disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sanofi France
Organisme : Sanofi, China
Informations de copyright
© 2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
International Diabetes Federation. Diabetes atlas, 10th edition. 2021 https://diabetesatlas.org/atlas/tenth-edition/. Accessed April 4 2023
Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090-1101.
Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;317:2515-2523.
Yan Y, Wu T, Zhang M, Li C, Liu Q, Li F. Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population. BMC Public Health. 2022;22:1382.
Sun Y, Ni W, Yuan X, Chi H, Xu J. Prevalence, treatment, control of type 2 diabetes and the risk factors among elderly people in Shenzhen: results from the urban Chinese population. BMC Public Health. 2020;20:998.
Hu C, Jia W. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes. 2018;67:3-11.
Jia W, Weng J, Zhu D, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev. 2019;35:e3158.
Davies MJ, D'Alessio DA, Fradkin J, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia. 2018;2018(61):2461-2498.
Ji L, Zhang P, Zhu D, et al. Observational registry of basal insulin treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: real-life use of basal insulin in China. Diabetes Obes Metab. 2017;19:822-830.
Handelsman Y, Muskiet MHA, Meneilly GS. Combining GLP-1 receptor agonists and basal insulin in older adults with type 2 diabetes: focus on lixisenatide and insulin glargine. Adv Ther. 2019;36:3321-3339.
Blumer I, Clement M. Type 2 diabetes, hypoglycemia, and basal insulins: ongoing challenges. Clin Ther. 2017;39:S1-S11.
Meier JJ, Rosenstock J, Hincelin-Méry A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38:1263-1273.
Rayner CK, Wu T, Aroda VR, et al. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: a network meta-analysis. Diabetes Obes Metab. 2021;23:136-146.
Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403-412.
National Medical Products Administration China. Delivery of drug approval certificates [in Chinese]. 2023. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230113151759128.html. Accessed 19 July 2023.
Pharmaceutical and Medical Devices Agency Japan. New drugs approved in FY 2019. 2020. https://www.pmda.go.jp/files/000235289.pdf. Accessed 16 May 2023.
US Food and Drug Administration. Soliqua® 100/33 (Insulin Glargine and Lixisenatide) Injectin, for Subcutaneous Use: Prescribing Information. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208673s012lbl.pdf. Accessed 16 May 2023.
European Medicines Agency. Suliqua (insulin glargine and lixisenatide): summary of product characteristics. 2017 https://www.ema.europa.eu/en/documents/product-information/suliqua-epar-product-information_en.pdf. Accessed 16 May 2023.
Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39:2026-2035.
Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39:1972-1980.
Rosenstock J, Emral R, Sauque-Reyna L, et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care. 2021;44:2361-2370.
Blonde L, Rosenstock J, del Prato S, et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial. Diabetes Care. 2019;42:2108-2116.
Watada H, Takami A, Spranger R, Amano A, Hashimoto Y, Niemoeller E. Efficacy and safety of 1:1 fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide in Japanese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: the LIXILAN JP-O1 randomized clinical trial. Diabetes Care. 2020;43:1249-1257.
Terauchi Y, Nakama T, Spranger R, Amano A, Inoue T, Niemoeller E. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: a randomized, 26-week, open-label, multicentre study: the LixiLan JP-O2 randomized clinical trial. Diabetes Obes Metab. 2020;22:14-23.
Kaneto H, Takami A, Spranger R, Amano A, Watanabe D, Niemoeller E. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: the LixiLan JP-L randomized clinical trial. Diabetes Obes Metab. 2020;22:3-13.
Yang W, Dong X, Li Q, et al. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/ml or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: the LixiLan-O-AP randomized controlled trial. Diabetes Obes Metab. 2022;24:1522-1533.
Yuan X, Guo X, Zhang J, et al. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/ml in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: results from the LixiLan-L-CN randomized controlled trial. Diabetes Obes Metab. 2022;24:2182-2191.
Chinese Diabetes Society, Dalong Z, Guideline for the prevention and treatment of type 2 diabetes mellitus in China. Edition. Chin J Diabetes. 2020;2021(13):315-409.
The State Council: The People's Republic of China. Notice of the General Office of the State Council on issuing the National Health Plan for the 14th Five-Year Plan [in Chinese]. 2022. https://www.gov.cn/zhengce/zhengceku/2022-05/20/content_5691424.htm?eqid=fd5f6db300002dd3000000066463059a. Accessed 20 November 2023.
Chen W-C, Lee C-C, Chien M-N, Liu S-C, Wang C-H, Yang W-S. Blood glucose management of type 2 diabetes in the older people. Int J Gerontol. 2018;12:170-174.
Giorgino F, Caruso I, Napoli R. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: a simplified approach to glycemic control in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2020;170:108478.
Trujillo JM, Roberts M, Dex T, Chao J, White J, LaSalle J. Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes Obes Metab. 2018;20:2690-2694.
Handelsman Y, Chovanes C, Dex T, et al. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications. 2019;33:236-242.
Terauchi Y, Yabe D, Kaneto H, et al. Benefits of the fixed-ratio combination of insulin glargine 100 units/ml and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: a subgroup and time-to-control analysis of the LixiLan JP phase 3 trials. Diabetes Obes Metab. 2020;22:35-47.
Home PD, McCrimmon RJ, Rosenstock J, et al. Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics. Diabetes Obes Metab. 2023;25:656-663.